94 related articles for article (PubMed ID: 31538838)
1. Detection of
Anyanwu NCJ; Ella EE; Aminu M; Kazeem HM
J Immunoassay Immunochem; 2019; 40(6):605-616. PubMed ID: 31538838
[TBL] [Abstract][Full Text] [Related]
2. Common KRAS and NRAS gene mutations in sporadic colorectal cancer in Northeastern Iranian patients.
Hamzehzadeh L; Khadangi F; Ghayoor Karimiani E; Pasdar A; Kerachian MA
Curr Probl Cancer; 2018 Nov; 42(6):572-581. PubMed ID: 29921458
[TBL] [Abstract][Full Text] [Related]
3. [NRAS Gene Expression and Its Clinical Significance in Patients with Acute Myeloid Leukemia].
Li TT; Li J; Geng YH; Zhang F; Liu L; Yang YL
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2020 Feb; 28(1):76-81. PubMed ID: 32027256
[TBL] [Abstract][Full Text] [Related]
4. [Characterization of genetic alterations in primary human melanomas carrying BRAF or NRAS mutation].
Lázár V
Magy Onkol; 2013 Jun; 57(2):96-9. PubMed ID: 23795354
[TBL] [Abstract][Full Text] [Related]
5. Dominant role of oncogene dosage and absence of tumor suppressor activity in Nras-driven hematopoietic transformation.
Xu J; Haigis KM; Firestone AJ; McNerney ME; Li Q; Davis E; Chen SC; Nakitandwe J; Downing J; Jacks T; Le Beau MM; Shannon K
Cancer Discov; 2013 Sep; 3(9):993-1001. PubMed ID: 23733505
[TBL] [Abstract][Full Text] [Related]
6. Prognostic significance of BRAF and NRAS mutations in melanoma: a German study from routine care.
Heppt MV; Siepmann T; Engel J; Schubert-Fritschle G; Eckel R; Mirlach L; Kirchner T; Jung A; Gesierich A; Ruzicka T; Flaig MJ; Berking C
BMC Cancer; 2017 Aug; 17(1):536. PubMed ID: 28797232
[TBL] [Abstract][Full Text] [Related]
7. NRAS mutations in de novo acute leukemia: prevalence and clinical significance.
Dunna NR; Vuree S; Anuradha C; Sailaja K; Surekha D; Digumarti RR; Rao VR; Yadav SK; Reddy R; Vishnupriya S
Indian J Biochem Biophys; 2014 Jun; 51(3):207-10. PubMed ID: 25204082
[TBL] [Abstract][Full Text] [Related]
8. SP174 Antibody Lacks Specificity for NRAS Q61R and Cross-Reacts With HRAS and KRAS Q61R Mutant Proteins in Malignant Melanoma.
Felisiak-Goląbek A; Inaguma S; Kowalik A; Wasąg B; Wang ZF; Zięba S; Pięciak L; Ryś J; Kopczynski J; Sarlomo-Rikala M; Góźdź S; Lasota J; Miettinen M
Appl Immunohistochem Mol Morphol; 2018 Jan; 26(1):40-45. PubMed ID: 29206715
[TBL] [Abstract][Full Text] [Related]
9. The clinical significance of BRAF and NRAS mutations in a clinic-based metastatic melanoma cohort.
Ekedahl H; Cirenajwis H; Harbst K; Carneiro A; Nielsen K; Olsson H; Lundgren L; Ingvar C; Jönsson G
Br J Dermatol; 2013 Nov; 169(5):1049-55. PubMed ID: 23855428
[TBL] [Abstract][Full Text] [Related]
10. Clinicopathological characteristics and mutation profile of BRAF and NRAS mutation in cutaneous melanomas in the Western Turkish population.
Evrenos MK; Temiz P; Çam FS; Yaman M; Yoleri L; Ermertcan AT
Turk J Med Sci; 2018 Oct; 48(5):973-979. PubMed ID: 30384563
[TBL] [Abstract][Full Text] [Related]
11. Mutation-specific effects of NRAS oncogenes in colorectal cancer cells.
Kuhn N; Klinger B; Uhlitz F; Sieber A; Rivera M; Klotz-Noack K; Fichtner I; Hoffmann J; Blüthgen N; Falk C; Sers C; Schäfer R
Adv Biol Regul; 2021 Jan; 79():100778. PubMed ID: 33431353
[TBL] [Abstract][Full Text] [Related]
12. Clinical Features and Outcomes of Patients with Colorectal Cancers Harboring NRAS Mutations.
Cercek A; Braghiroli MI; Chou JF; Hechtman JF; Kemeny N; Saltz L; Capanu M; Yaeger R
Clin Cancer Res; 2017 Aug; 23(16):4753-4760. PubMed ID: 28446505
[No Abstract] [Full Text] [Related]
13. Comprehensive survey of HRAS, KRAS, and NRAS mutations in proliferative thyroid lesions from an ethnically diverse population.
Schulten HJ; Salama S; Al-Ahmadi A; Al-Mansouri Z; Mirza Z; Al-Ghamdi K; Al-Hamour OA; Huwait E; Gari M; Al-Qahtani MH; Al-Maghrabi J
Anticancer Res; 2013 Nov; 33(11):4779-84. PubMed ID: 24222113
[TBL] [Abstract][Full Text] [Related]
14. Testing for
Sadlecki P; Grzanka D; Grabiec M
Dis Markers; 2018; 2018():1497879. PubMed ID: 29682098
[TBL] [Abstract][Full Text] [Related]
15. Application of BRAF, NRAS, KRAS mutations as markers for the detection of papillary thyroid cancer from FNAB specimens by pyrosequencing analysis.
Park SJ; Sun JY; Hong K; Kwak JY; Kim EK; Chung WY; Choi JR
Clin Chem Lab Med; 2013 Aug; 51(8):1673-80. PubMed ID: 23585181
[TBL] [Abstract][Full Text] [Related]
16. NRAS mutant E132K identified in young-onset sporadic colorectal cancer and the canonical mutants G12D and Q61K affect distinct oncogenic phenotypes.
Yu RTD; Garcia RL
Sci Rep; 2020 Jul; 10(1):11028. PubMed ID: 32620824
[TBL] [Abstract][Full Text] [Related]
17. Mutation of NRAS is a rare genetic event in ovarian low-grade serous carcinoma.
Xing D; Suryo Rahmanto Y; Zeppernick F; Hannibal CG; Kjaer SK; Vang R; Shih IM; Wang TL
Hum Pathol; 2017 Oct; 68():87-91. PubMed ID: 28873354
[TBL] [Abstract][Full Text] [Related]
18. Mutational Status of NRAS and BRAF Genes and Protein Expression Analysis in a Series of Primary Oral Mucosal Melanoma.
Hsieh R; Nico MM; Camillo CM; Oliveira KK; Sangueza M; Lourenço SV
Am J Dermatopathol; 2017 Feb; 39(2):104-110. PubMed ID: 28134726
[TBL] [Abstract][Full Text] [Related]
19. Prognostic impact of KRAS, NRAS, BRAF, and PIK3CA mutations in primary colorectal carcinomas: a population-based study.
Palomba G; Doneddu V; Cossu A; Paliogiannis P; Manca A; Casula M; Colombino M; Lanzillo A; Defraia E; Pazzola A; Sanna G; Putzu C; Ortu S; Scartozzi M; Ionta MT; Baldino G; Sarobba G; Capelli F; Sedda T; Virdis L; Barca M; Gramignano G; Budroni M; Tanda F; Palmieri G
J Transl Med; 2016 Oct; 14(1):292. PubMed ID: 27737711
[TBL] [Abstract][Full Text] [Related]
20. RAS status in Korean patients with stage III and IV colorectal cancer.
Lee WS; Lee JN; Baek JH; Park YH
Clin Transl Oncol; 2015 Sep; 17(9):751-6. PubMed ID: 25997687
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]